NULISA: Ultra-Sensitive & Multiplex Immunoassay Platform for Fluid-Based Neurodegenerative Biomarker Detection

Time: 9:00 am
day: Conference Day Two


  • New biomarker assay technology, NULISA™ – with ultra-sensitive femtogram level detection with proprietary background suppression technology
  • Unique NULISA CNS Disease Panel detecting nearly 120 critical biomarkers covering Alzheimer’s and Parkinson's Disease as well as other CNS-related diseases
  • Ultra-sensitive NULISA technology holds great promise to enable early detection and monitoring of neurodegenerative diseases to aid in new therapeutic development